These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35613320)

  • 1. An adapted consensus protein design strategy for identifying globally optimal biotherapeutics.
    Liu Y; Tsang K; Mays M; Hansen G; Chiecko J; Crames M; Wei Y; Zhou W; Fredrick C; Hu J; Liu D; Gebhard D; Huang ZF; Datar A; Kronkaitis A; Gueneva-Boucheva K; Seeliger D; Han F; Sen S; Kasturirangan S; Scheer JM; Nixon AE; Panavas T; Marlow MS; Kumar S
    MAbs; 2022; 14(1):2073632. PubMed ID: 35613320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
    Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing developability early in the discovery process for novel biologics.
    Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
    MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain.
    Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR
    MAbs; 2020; 12(1):1787121. PubMed ID: 32658605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics.
    Licari G; Martin KP; Crames M; Mozdzierz J; Marlow MS; Karow-Zwick AR; Kumar S; Bauer J
    Mol Pharm; 2023 Feb; 20(2):1096-1111. PubMed ID: 36573887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosting antibody developability through rational sequence optimization.
    Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
    MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
    Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
    MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences.
    Coffman J; Marques B; Orozco R; Aswath M; Mohammad H; Zimmermann E; Khouri J; Griesbach J; Izadi S; Williams A; Sankar K; Walters B; Lin J; Hepbildikler S; Schiel J; Welsh J; Ferreira G; Delmar J; Mody N; Afdahl C; Cui T; Khalaf R; Hanke A; Pampel L; Parimal S; Hong X; Patil U; Pollard J; Insaidoo F; Robinson J; Chandra D; Blanco M; Panchal J; Soundararajan S; Roush D; Tugcu N; Cramer S; Haynes C; Willson RC
    Biotechnol Bioeng; 2020 Jul; 117(7):2100-2115. PubMed ID: 32255523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.
    Martin KP; Grimaldi C; Grempler R; Hansel S; Kumar S
    MAbs; 2023; 15(1):2191301. PubMed ID: 36998195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Developability of an Antigen Binding Fragment by Aspartate Substitutions.
    Sakhnini LI; Greisen PJ; Wiberg C; Bozoky Z; Lund S; Wolf Perez AM; Karkov HS; Huus K; Hansen JJ; Bülow L; Lorenzen N; Dainiak MB; Pedersen AK
    Biochemistry; 2019 Jun; 58(24):2750-2759. PubMed ID: 31117388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy.
    Lobo SA; Bączyk P; Wyss B; Widmer JC; Jesus LP; Gomes J; Batista AP; Hartmann S; Wassmann P
    J Pharm Biomed Anal; 2021 Jan; 192():113650. PubMed ID: 33065403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we discover developable antibody-based biotherapeutics?
    Bauer J; Rajagopal N; Gupta P; Gupta P; Nixon AE; Kumar S
    Front Mol Biosci; 2023; 10():1221626. PubMed ID: 37609373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
    Thorsteinson N; Comeau SR; Kumar S
    Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
    Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
    MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.